Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with β-thalassaemia major: Comparison between different chelation regimens

European Journal of Haematology

Volumn 78, Issue 1, 2007, Pages 52-57

  Christoforidis, Athanasios ^a   Haritandi, Afroditi ^b   Tsatra, Ioanna ^a   Tsitourides, Ioannis ^c   Karyda, Stavroula ^a   Athanassiou Metaxa, Miranda ^a  

^a Aristotle University of Thessaloniki   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

thalassaemia; Combined therapy; Heart; Liver; Magnetic resonance imaging

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

ADOLESCENT; ADULT; ARTICLE; CHELATION THERAPY; CHILD; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG EFFICACY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FERRITIN BLOOD LEVEL; HEART MUSCLE; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER BIOPSY; LIVER LEVEL; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHELATION THERAPY; CHILD; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; PROSPECTIVE STUDIES; PYRIDONES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 33845900683     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.0902-4441.2006.t01-1-EJH3013.x     Document Type: Article

References (31)

1. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci 2005;1054:40-7.
2. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000 15;95:1229-36.
3. Miskin H, Yaniv I, Berant M, Hershko C, Tamary H. Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. Eur J Haematol 2003;70:398-403.
4. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-84.
5. Jensen PD. Evaluation of iron overload. Br J Haematol 2004;24:697-711.
6. Brittenham GM, Badman DG. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Workshop. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003;101:15-9.
7. Gossuin Y, Roch A, Muller RN, Gillis P. Relaxation induced by ferritin and ferritin-like magnetic particles: the role of proton exchange. Magn Reson Med 2000;43:237-43.
8. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, Coates TD. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005;106:1460-5.
9. Chan YL, Li CK, Lam CW, Yu SC, Chik KW, To KF, Yeung DK, Howard R, Yuen PM. Liver iron estimation in beta-thalassaemia: comparison of MRI biochemical assay and histological grading. Clin Radiol 2001;56:911-6.
10. Bonetti MG, Castriota-Scanderbeg A, Criconia GM, Mazza P, Sacco M, Amurri B, Masi C. Hepatic iron overload in thalassemic patients: proposal and validation of an MRI method of assessment. Pediatr Radiol 1996;26:650-6.
11. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-9.
12. Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V, Deugnier Y. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004;363:357-62.
13. Mavrogeni SI, Markussis V, Kaklamanis L, Tsiapras D, Paraskevaidis I, Karavolias G, Karagiorga M, Douskou M, Cokkinos DV, Kremastinos DT. A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. Eur J Haematol 2005;75:241-7.
14. Cohen A. Management of iron overload in the pediatric patient. Hematol Oncol Clin North Am 1987;1:521-544.
15. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology (Am Soc Hematol Educ Program) 2001;47-61.
16. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 1983;36:539-45.
17. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Hematology (Am Soc Hematol Educ Program) 2004;14-34.
18. Christoforidis A, Haritandi A, Tsitouridis I, Tsatra I, Tsantali H, Karyda S, Dimitriadis AS, Athanassiou-Metaxa M. Correlative study of iron accumulation in liver, myocardium, and pituitary assessed with MRI in young thalassemic patients. J Pediatr Hematol Oncol 2006;28:311-5.
19. Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology (Am Soc Hematol Educ Program) 2003;40-61.
20. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61.
21. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004;103:1934-6.
22. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002;360:516-20.
23. Pepe A, Lombardi M, Positano V, Cracolici E, Capra M, Malizia R, Prossomariti L, De Marchi D, Midiri M, Maggio A. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. Eur J Haematol 2006;76:183-92.
24. Shalev O, Repka T, Goldfarb A, Grinberg L, Abrahamov A, Olivieri NF, Rachmilewitz EA, Hebbel RP. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood 1995;86:2008-13.
25. de Franceschi L, Shalev O, Piga A, Collell M, Olivieri O, Corrocher R, Hebbel RP, Brugnara C. Deferiprone therapy in homozygous human beta-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity. J Lab Clin Med 1999;133:64-9.
26. Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin 2006;30:239-49.
27. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003;121:187-9.
28. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103:361-4.
29. Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol 2006:85;315-9.
30. Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol 2001:38;360-6.
31. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001;138:130-8.